Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Böblingen – page 8

944 clinical trials in Böblingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Böblingen at a glance
944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

944 trials in Böblingen

Open in trial search

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT324
  • Sponsor:BioNTech SE

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD8965
  • Sponsor:AstraZeneca AB

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Böblingen

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focusing on multiple sclerosis treatments, including studies comparing new therapies like fenebrutinib and frexalimab with established treatments. Several trials are investigating novel approaches for both relapsing and primary progressive forms of MS.

  • Relapsing Multiple Sclerosis
  • Primary Progressive MS
  • Brain Inflammation

Additional studies explore innovative treatments for migraine prevention in patients who haven't responded to conventional therapies.

02 Mental Health Studies

Comprehensive research into major depressive disorder and schizophrenia, evaluating new therapeutic approaches. Trials include testing novel compounds for depression with anhedonia and long-term safety studies for schizophrenia treatments.

  • Depression Treatment
  • Schizophrenia Management
  • ADHD Therapy

Studies also examine new formulations for ADHD treatment in adults, comparing immediate and modified-release medications.

03 Oncology Research

Innovative trials in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate both neoadjuvant and adjuvant therapeutic approaches.

  • Triple-Negative Breast Cancer
  • HER2-Negative Breast Cancer
  • Rectal Cancer

Additional research examines treatment strategies for locally advanced rectal cancer, comparing pre- and post-surgical interventions.

04 Neurodegenerative Conditions

Critical research into Alzheimer's disease and related conditions, with studies focusing on treating associated symptoms like psychosis and agitation in dementia patients.

  • Alzheimer's Psychosis
  • Dementia Management
  • Behavioral Symptoms

These trials aim to improve quality of life for patients with neurodegenerative disorders through targeted symptom management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.